A. P. G. M. V. Samaraweera

A. P. G. M. V. Samaraweera

Auto-generated profile, based on publicly available information

A. P. G. M. V. Samaraweera


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
UGUdukumbura Mudunkothge Thisari Maleesha Gunathilaka
Udukumbura Mudunkothge Thisari Maleesha Gunathilaka
ADA.B.K.Lahiru Dhananjaya
A.B.K.Lahiru Dhananjaya
SPShalika Parakatawella
Shalika Parakatawella
ASA. P. G. M. V. Samaraweera
A. P. G. M. V. Samaraweera
Conventional systemic drug delivery often yields low efficacy and significant side effects due to off-target accumulation and rapid clearance. While nanoscale carriers leverage the enhanced permeability and retention (EPR) effect, this passive targeting is unreliable because tumor vascular heterogeneity leads to widely variable nanoparticle accumulation. As an alternative, untethered micro- and nanorobots (MNRs) have been engineered to actively navigate through complex fluids and autonomously deliver payloads to previously inaccessible sites. These autonomous biohybrids integrate nanoscale actuators, sensors, and computational units to enable precise, on-demand therapeutic actions at the cellular level. In particular, integrating artificial intelligence endows nanorobots with advanced sensing and decision-making capabilities: they can analyze molecular biomarkers and map biological pathways in real time to determine optimal treatment plans, yielding highly personalized, responsive therapies with enhanced efficacy. We also examine strategies for post-treatment removal of MNRs, emphasizing immune-compatible, biodegradable designs that allow metabolic clearance. This review aims to provide a comprehensive, in-depth, and nuanced examination of nanorobots in medical applications mainly in cancer treatments. Finally, we highlight remaining technical, manufacturing, regulatory and ethical challenges such as ensuring biocompatibility, scalable fabrication, and rigorous safety evaluation that must be ad-dressed for clinical translation.